Lupin Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Turnaround complete, growth accelerating: US revenue hit \$925 mn in FY25, up 13% YoY, with complex generics now 34% of the US business and a pipeline that targets 55% in five years.
• Margins structurally improved but masked: EBITDA margin of 23.2% absorbed a ₹100 cr R&D step-up and ₹50 cr PLI decline; adjusted margin was ~26%, and management guides at least 100 bps expansion this year.
• FY26 is the injectables year: Glucagon, Liraglutide, and Risperdal Consta® approvals expected in coming months, with Tolvaptan already launched and contributing materially in H1.
• India bets on chronic and reach: Chronic share to move from 64% to 69-70% by FY30; 400-500 reps added annually; trade generics spun out as a separate subsidiary to capture tier-2/3 growth.
• What to watch next quarter: Tolvaptan revenue trajectory and competitor entry timing, injectables approval cadence, and whether respiratory in India bounces back as guided.

US Business: The Complex Generics Engine

• Turnaround delivered: The US business grew from a slump to \$925 mn, a 21% CAGR over three years, driven by a deliberate pivot to complex generics. Complex generics went from 2% of US revenue in FY20 to 34% in FY25, with a target of 55% in five years.
• Spiriva® as proof of capability: Lupin was the first Indian company to launch a DPI in the US, approved in 2023, and remains the sole generic. The product took five years from filing to FDA approval, creating a barrier management expects will keep it exclusive for at least another 12 months.
• Tolvaptan launched, tail expected to be sticky: Launched earlier this week relative to the call date, Tolvaptan is a REMS product distributed through specialty channels. Management now believes the tail will be longer than initially expected because specialty distributors prefer long-term relationships, and the six-month exclusivity period will capture more value than the post-competition period.
• FY26 injectables wave: Glucagon and Liraglutide approvals expected July-August; Risperidone long-acting injectable approval expected in the next couple of months. These make H2 more injectables-heavy, while H1 is Tolvaptan-heavy, making the US year front-loaded.
• Pipeline depth: Over 60 filings in the next five years focused on First-to-File and Para 4 products. FY27 brings three inhalation products, two injectables, two biosimilars, and the first specialty product. FY28 and FY29 add more inhalation, injectables, and biosimilars.
• Albuterol pricing pressure acknowledged: With additional competition, pricing pressure has begun, though management did not quantify the impact.

Nilesh Gupta: "If you see the last three years, you see that consistent 21% growth in the business. We're very proud of the way that we have turned this around."

India: Chronic Shift and Reach Expansion

• Growth above market, despite headwinds: India grew 8.4% in FY25 vs market growth of 8%, even as the in-license portfolio declined 12% and respiratory stayed sluggish. Management expects the in-license erosion to have largely played out, with double-digit growth resuming in FY26.
• Chronic mix improving: Chronic share moved from sub-60% to 64%, with a target of 69-70% by FY30. Cardiovascular grew 30% ahead of market; diabetes saw good volume growth.
• Field force expansion: Over 2,000 representatives to be added in the next four to five years, at a pace of 400-500 per year. A new nebulization task force and an expanded Uday Division for extra-urban markets are scaling up this year.
• Trade generics spun out: Lupin Life Sciences, a wholly-owned subsidiary, was launched last year to focus on trade generics in tier-2 and tier-3 towns, building on Lupin brand equity.
• Insulin push: The Huminsulin® brand acquisition from Lilly, combined with Novo Nordisk exiting the insulin cartridge market, gives Lupin an opportunity to gain another 6-7% market share.
• Respiratory bet: Respiratory has been sluggish for two years, but management expects a bounce-back this year, supported by the nebulization task force and differentiated products like Difizma and Vilfuro.

Nilesh Gupta: "We're ranked number eight. We're not happy at all with this rank. I think we have to be in the top five but currently number eight."

Margin Walk and Cost Story

• Q4 margin optically compressed: EBITDA margin of 23.2% included a ₹100 cr sequential increase in R&D spend and a ₹50 cr decline in PLI claimed. Adjusted for these, the margin would have been close to 26%.
• Full-year improvement: FY25 EBITDA margin was 23.7%, up from ~19% in FY24. Gross margins improved from 64% to 69.2% over the same period, driven by new products, alternate vendor development, and productivity across R&D, manufacturing, and sales force.
• Cost reduction program delivered: A mission to reduce costs by ₹750-1,000 cr succeeded. Other operating expenses fell from 30.4% of revenue in FY20 to under 30%. Operating working capital improved to ~110 days, among the best in the industry.
• Adjacencies still a drag: Digital, diagnostics, API CDMO, and the biosimilars business together reduced overall FY25 margin by ~3.5 to 3.7 percentage points. Diagnostics is targeted to be EBITDA-positive in FY27.
• R&D to keep rising: R&D spend has grown at over 20% CAGR over the last 3-4 years and will rise at least another 10-15% in FY26, reaching upward of 8.5% of sales, as the pipeline tilts toward more complex products.
• FY26 margin guidance: Margins expected to expand by at least ~100 bps this year, with further expansion as the pipeline evolves. Management stated it can afford increased R&D investment and still grow margins.

Ramesh Swaminathan: "This particular quarter, we ended up at 23.2%, but this is after taking into account a couple of things. The first is, essentially, you would see a INR 100 crore increase when it comes to the R&D expenditure and there has been a decline in terms of PLI that we claimed for this quarter, which is about INR 50 odd crores. So if you would adjust for these two, the actual EBITDA margin would have been close to about 26%."

Biosimilars, Specialty, and Adjacencies

• Biosimilars strategy adapted: With FDA reducing interchangeability study requirements and a private-label model emerging, Lupin now treats biosimilars as a complex generic play, focusing on products with limited competitors. Pegfilgrastim is attractive because Lupin can enter with a new ASP; ophthalmic distributor relationships (Cencora covers 70% of ophthalmic clinics) enable entry for Ranibizumab and Aflibercept.
• Etanercept global rollout: Already a material contributor in Europe, Japan, Southeast Asia, and Latin America. US commercialization is planned around the 2029 patent expiry. Australia launch expected this year.
• Specialty build via M&A and 505(b)(2): Focus areas are respiratory and CNS/neurology, with opportunistic moves in other areas. The strategy targets accretive, late-stage, de-risked pipeline assets with creative structures to mitigate P&L risk. Capital allocation guardrails: debt-to-EBITDA ~2:1, financial returns ~20%, payback 4-6 years.
• Nanomi platform: Acquired for long-acting injectables; Risperdal Consta® is the first validation product. The platform is being explored for 505(b)(2) opportunities, peptides, and biologics, with the biggest opportunity being the ability to innovate and build a novel pipeline.
• CDMO still building: Lupin Manufacturing Solutions is fully functional as a separate entity with a separate office and global team. Revenues are not meaningful yet; management expects a meaningful number in two years.

Vinita Gupta: "Having said that going forward now given the barriers are reducing it becomes like a complex generic play for us. So, the focus is on products where the number of competitors are limited or where we can be one of few in the market place."

Quality, Compliance, and Operational Excellence

• Compliance turnaround: Down to two sites in non-satisfactory compliance status, from five in FY20. Three sites (Pithampur, Goa, Somerset) moved from warning letters to VAI status. EIRs from about five sites received in the last year. A biotech facility pending US approval has been added to the list.
• Mandideep and Tarapur: Management is confident these will be cleared in the near future. No pending products from these sites, so FDA has no urgency to inspect, but the goal is for all sites to be inspection-ready at any time.
• Global Tech Ops delivering: OTIF levels at 100% globally, India at 98%. Lowest-ever backorder and lowest-ever failure-to-supply. Air-ocean freight ratio at an all-time low.
• Cost leadership: USD 50 mn delivered last year through alternate vendor development, freight optimization, and yield improvement. Technology investments include Kinaxis for global planning, paperless sites, automation, continuous flow reactors, and robotics in some plants.

Tariffs, Policy, and External Risks

• Tariff outlook cautiously optimistic: Management is hopeful that bilateral trade negotiations between India and the US, combined with the fact that 50% of US prescriptions come from India, will result in zero or limited tariffs on drugs. A recent Trump administration statement sounded promising.
• MFN executive order: Expected to impact the brand side of the business more than generics, focused on the highest-value drugs. Management is not very concerned at this time, expecting litigation and Big Pharma to fight it.
• IRA pill penalty under review: The 9-year negotiation window for small molecules vs 13 years for biologics is under active review; management expects it could land in the same place as biologics.
• US manufacturing flexibility: Lupin is already investing in an Ellipta Line and Respimat Line at Coral Springs, decisions made before the current administration. The company is open to setting up more US manufacturing if incentives or grants are offered, and is in dialogue with the National Security Council as part of a White House initiative on essential drugs.
• Semaglutide ready for LOE: Developing both in-house (tablet) and with partners (injectable), ready for the March 2026 loss of exclusivity. Management expects the market to expand as prices come down.

Vinita Gupta: "We are hopeful that, based on the bilateral trade negotiation between India and the US, the importance of Indian pharma sector in the US, given 50% of the prescriptions in the US come from India, that we are going to be able to convince the stakeholders to have either zero tariff or limited tariff on drugs from India."

Guidance & Commitments

Key Metrics